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course of SIV infection - a time when SIV and HIV are known to cause irreversible damage to 48 the immune system. Oddly, we found that the immune system did not recognize SPgV;; a finding 49 that warrants further investigation. Overall, this study greatly expands on our understanding of 50 the pegiviruses and their interaction with the immune system. 51 52 53
Introduction: 54
Human pegivirus (HPgV) -formerly known as GB virus C (GBV-C) and also as Hepatitis G 55 Virus (HGV) -is a positive-sense, single-stranded RNA virus in the Pegivirus genus of the 56 Flaviviridae family (1) . HPgV infects one out of six humans globally and is frequently transmitted 57 via blood products (2). Little is known about the molecular biology of pegiviruses and the natural 58 course of HPgV infection is poorly understood. However, HPgV causes persistent, high-titer 59 viremia without eliciting symptoms or overt signs of disease (3, 4). Interestingly, epidemiological 60 studies have found that people infected with human immunodeficiency virus (HIV) experience 61 reduced disease when they are co-infected with HPgV. Specifically, HIV-infected individuals co-62 infected with HPgV are protected from HIV-induced CD4 T cell depletion (5-8) and pathological 63 immune activation (9-12). These individuals also experience a 2.5-fold reduction in all-cause 64 mortality relative to HIV+ individuals not co-infected with HPgV (see (13) for a meta-analysis 65 and (2) for a review). However, the timing and mechanistic underpinnings of this protective 66 association are not known, in part because most data on HIV+HPgV co-infection comes from 67 cross-sectional studies performed during the chronic phase of HIV infection. In particular, the 68 impact of HPgV infection on acute phase HIV infection -a period during which pathologic 69 changes in the HIV-infected host are most dramatic (14) - has not been studied. As such, the 70 impact of HPgV co-infection on the natural course of HIV infection, and the mechanism(s) by 71 Table S1 ). Four macaques received intravenous inoculations of plasma 93 containing 2.29×10 7 genome copies (gc) of SPgV measured by quantitative RT-PCR, as done 94 previously (17). These infections achieved initial peak titers between 7.30×10 6 and 2.66×10 7 95 gc/ml of plasma between 7 and 14 days post SPgV infection ( Fig.  1A) , similar to what had been 96 observed previously. By 26 days post-SPgV infection viral loads had established a high-titer 97 steady-state (average of 2.02×10 7 gc/ml) and all eight macaques were inoculated intra-rectally 98 with 7,000 tissue-culture-infectious-dose (TCID) 50 of SIVmac239. 99 SIV plasma viral loads followed a typical trajectory during acute phase, reaching peak 100 titers between 1.01×10 7 and 5.25×10 7 gc/ml of plasma between days 11 and 13 post-SIV 101 infection in all eight macaques ( Fig.  1B ). No differences in peak SIV plasma titer or post-peak 102 nadir were observed between the SIV+SPgV co-infected and SIV-only groups (Fig. 1C ). To determine whether SPgV impacted subsequent SIV viral load trajectory, we followed the 104 macaques for 126 days after SIV infection. Within each group, we observed a wide range of 105 viral load set-point titers. However, there was not a significant difference in SIV viral loads 106 between the SIV+SPgV group and the SIV-only group at any time point ( Fig  1D) . 107 108 109 110 SPgV from the other two macaques revealed no protein-coding mutations (Table S2) , 123
Acute SIV infection reduces SPgV viremia. Beginning as early as day 5 of SIV infection (day
suggesting that an SPgV-specific immune response and subsequent mutational escape was not 124 responsible for the measured decrease in SPgV viral loads. 125
We hypothesized that the reduction in SPgV viral load during acute SIV infection was the 126 result of inflammation induced by SIV, which has been reported to occur secondary to microbial 127 translocation from the gut lumen (14). Thus, we infected eight macaques intravenously with 128 2.29×10 7 gc of SPgV and treated four of these macaques with dextran sulfate sodium (DSS) on 129 day 26 post-SPgV infection to induce microbial translocation (20, 21). DSS treatment had no 130 significant impact on SPgV viral loads, suggesting that inflammation caused by microbial 131 translocation during acute SIV infection was not responsible for the observed decline in SPgV 132 viral loads (Table  S3 ). 133 134
SPgV pre-infection does not prevent loss of peripheral CD4+ T cells. The absolute number 135
of circulating CD4+ T cells remains the most clinically-relevant marker of HIV/SIV disease 136 progression, and some studies of HIV+ human patients have shown a modest association 137 between HPgV co-infection and higher peripheral CD4+ T cell counts (5-8). Therefore, we 138 followed blood CD4+ T cell counts in both the SIV-only and SIV+SPgV groups. We observed an 139 initial drop in the circulating CD4+ T cells that corresponded with peak SIV viremia in all eight 140 animals which then recovered to near pre-SIV levels. However, there were no statistically 141 significant differences in the CD4+ T cell count between the SIV-only and SIV+SPgV groups 142 ( Fig.  2A ). An increase in the absolute number of circulating CD4+ T cells was observed prior to 143 SIV infection in the macaques infected with SPgV, although a concomitant increase was also 144 noted in the SPgV-naïve macaques during this time period, suggesting that this increase was 145 not due to SPgV infection. 146 147 clearly delineated a positive and negative population ( Fig  3A) . While the timing and magnitude 168 of activation following SIV infection varied by cell subset, we did not detect a significant 169 difference in the magnitude of peak activation, the time to peak activation, or the post-peak 170 nadir of activation between the SIV-only and SIV+SPgV groups within any subset ( Fig.  3B-D) . 171
SPgV pre-infection does not prevent loss of gut CD4+ T cells. The early loss of CD4+ T
Activation of immune cells in the gut and in lymph nodes, as measured by IHC staining for the 172 proliferation marker Ki67, showed a similar pattern (Fig.  4) 
SPgV infection does not induce activation of the immune system. Systemic viral infections 182
typically elicit a Th1-type immune response characterized by the activation of lymphocytes. To 183 examine the immune response to acute pegivirus infection, we trended markers of immune cell 184 activation by flow cytometry for 26 days following SPgV infection. Oddly, we saw no significant 185 changes from pre-infection baseline in the total number or activation state of circulating 186 lymphocytes during this time period despite high titers of SPgV. This is in stark contrast to SIV 187 infection, which elicited a robust increase in immune activation during the same timeframe ( 
SPgV Viral loads. A Taqman quantitative RT-PCR (qRT-PCR) assay was used to quantify viral 284
RNA for SPgV (forward primer: 5'-CGGTGTTCATGGCAGGTAT-3';; reverse primer: 5'-285 CAGTTACAGCCGCGTGTTT-3';; probe: 5'-6FAM-ATGCACCCTGATGTAAGCTGGGCAA-286 BHQ1-3'), as described previously (16). Reverse transcription and PCR were performed using 287 the SuperScript III One-Step qRT-PCR system (Invitrogen, Carlsbad, CA) on a LightCycler 480 288 instrument (Roche, Indianapolis, IN). Reverse transcription was carried out at 37°C for 15 289 minutes and then 50°C for 30 minutes followed by 2 minutes at 95°C, and then 50 cycles of 290 amplification as follows: 95°C for 15 sec and 60°C for 1 minute. The 20 µL reaction mixture 291 contained 5 µL of extracted RNA, MgSO 4 at a final concentration of 3.0 mM, with the two 292 amplification primers at a concentration of 500 nM and probe at a concentration of 100 nM. RNA 293 copy number was calculated using a standard curve that was sensitive down to 10 copies of 294 RNA transcript per reaction. 295 296 SIV viral loads. A Taqman qRT-PCR assay was used to quantify viral RNA for SIV (forward 297 primer:
5′-GTCTGCGTCATCTGGTGCATTC-3′;; reverse primer: 5′-298 CACTAGCTGTCTCTGCACTATGTGTTTTG-3′;; probe: 5'-6FAM-299 CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-BHQ1-3′), as described previously (31). 300
Cycling conditions were: 37°C for 15 min, 50°C for 30 min, and 95°C for 2 min, followed by 50 301 amplification cycles of 95°C for 15 sec and 62°C for 1 min with ramp times set to 3°C/sec. The 
